Browsing Tag
Ipsen
6 posts
How FIREFLY1 data positioned Ojemda for conditional EU approval in pediatric glioma
How FIREFLY1 data positioned Ipsen’s Ojemda for conditional EU approval in pediatric glioma and what it means for investors and competitors.
Ipsen secures global licensing option for Origami’s selective protein degrader platform
Ipsen has signed a global option deal with Origami Therapeutics for a rare CNS protein degrader. Find out what this signals for neuro drug strategy.
Ipsen stock edges higher as Japan clears Bylvay for rare liver disease — is the upside real for investors?
Ipsen (IPN) gains after Japan approves Bylvay for rare liver disease. See stock performance, analyst sentiment, and whether it’s time to buy, hold, or sell.
Will CABOMETYX secure EU approval for advanced neuroendocrine tumors after CHMP’s positive opinion?
Ipsen’s CABOMETYX receives EMA's CHMP backing for advanced neuroendocrine tumors; EU approval expected in 2025 following FDA nod.
Ipsen gets Bylvay FDA approval for cholestatic pruritus in Alagille syndrome
The US Food and Drug Administration (FDA) has granted approval to French biopharmaceutical company Ipsen for Bylvay (odevixibat)…
Ipsen to acquire American biopharma company Epizyme for $247m
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration…